Prescribing patterns and clinical perceptions of high-dose co-amoxiclav in upper respiratory tract infections: a nationwide study among otorhinolaryngologists
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20260658Keywords:
High dose co amoxiclav, URTIs, ENT surgeons, Prescribing patterns, Antimicrobial stewardshipAbstract
Background: Upper respiratory tract infections (URTIs) are a leading cause of outpatient visits and antibiotic use across age groups. Amoxicillin–clavulanate (co amoxiclav) is widely prescribed due to its activity against β lactamase–producing pathogens. High dose formulations (1 g) aim to enhance pharmacodynamic target attainment and clinical efficacy, particularly against less susceptible organisms. However, real world data on otorhinolaryngologists’ prescribing practices and perceptions of high dose co amoxiclav are limited.
Methods: A descriptive, questionnaire-based survey was conducted among otorhinolaryngologists attending the Annual National Conference of the Association of Otolaryngologists of India. A structured 10 item electronic questionnaire captured prescribing patterns, clinical indications, decision drivers, perceived effectiveness, safety, and patient compliance. Data was analysed using descriptive statistics.
Results: A total of 176 otorhinolaryngologists participated. Acute otitis media was the most common indication (52%), followed by acute tonsillitis (25%), sinusitis (16%), and pharyngitis (7%). Overall, 70% of respondents prescribed high dose (1g) co amoxiclav sometimes or often, with 59% using it as first line therapy. Clinical efficacy (52%) and once daily dosing convenience (21%) were the main drivers of use. Prescribing decisions were guided by clinical guidelines in 45% of cases. Satisfaction with outcomes was high (93%). Diarrhoea (66%) and nausea (21%) were the most frequently reported adverse effects. Dosing frequency was considered the key determinant of patient compliance (56%). High dose (1g) co amoxiclav was perceived as more effective than other antibiotics by 77% and safer by 87% of respondents.
Conclusion: High dose co amoxiclav (1 g) is widely accepted by otorhinolaryngologists for URTIs, supported by perceived efficacy, convenient dosing, favourable safety, and alignment with antimicrobial stewardship principles.
Metrics
References
National Institute for Health and Clinical Excellence (NICE). Respiratory tract infections (self-limiting): prescribing antibiotics. NICE Clinical Guideline CG69. London: NICE. 2008.
World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva: WHO. 2014.
Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):25247. DOI: https://doi.org/10.1101/cshperspect.a025247
White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53(1):3–20. DOI: https://doi.org/10.1093/jac/dkh050
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10. DOI: https://doi.org/10.1086/516284
Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255–9. DOI: https://doi.org/10.1097/00006454-199603000-00015
Jena D, Ghosh TK, Pal A, Pawar D, Sharma A. Exploring the therapeutic potential of high-dose co-amoxiclav (1g) in different clinical conditions: a review. Cureus. 2024;16(7):64717. DOI: https://doi.org/10.7759/cureus.64717
Hoberman A, Paradise JL, Rockette HE. Treatment of acute otitis media in children under 2 years of age. N Engl J Med. 2011;364(2):105–15. DOI: https://doi.org/10.1056/NEJMoa0912254
Pichichero ME. Acute otitis media: Part II. Treatment in an era of increasing antibiotic resistance. Am Fam Physician. 2000;61(8):2410–6.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310. DOI: https://doi.org/10.1016/S0149-2918(01)80109-0
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97. DOI: https://doi.org/10.1056/NEJMra050100
Gillies M, Ranakusuma A, Hoffmann T. Common harms from amoxicillin: a systematic review and meta-analysis. CMAJ. 2015;187(1):21–31. DOI: https://doi.org/10.1503/cmaj.140848
World Health Organization. WHO AWaRe classification of antibiotics for evaluation and monitoring of use. Geneva: WHO. 2021.
Downloads
Published
How to Cite
Issue
Section
